Improved overall survival (OS), progression-free survival (PFS) and confirmed objective response rate (ORR) were observed in the China subpopulation treated with TIVDAK compared to chemotherapy, ...

MADISON, Wis., Aug. 30, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the National Cancer Institute (NCI) ...

The UC Santa Cruz Colligan Clinical Diagnostic Laboratory (CCDL) has received its CLIA certificate of registration from the California Department of Public Health, which clears the way for it to begin ...

A new class of cancer drug has been pushed to an almost unimaginable level of potency in the lab, with researchers reporting a 20,000‑fold jump in tumor‑killing power while aiming to spare healthy ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License ...

TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients ...

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise, their toxicity to healthy tissue remains a major hurdle.

Gertrude B. Elion, a chemist working in the research laboratories of Burroughs Wellcome, revolutionized childhood cancer ...

Engineering professors at the University are creating a new kind of lab-grown cancer tumor that will make cancer research more accessible and affordable, revolutionizing the field. Bioengineering ...

Joan Brugge, Ph.D., in her office at Harvard Medical School. "I can't stop just because of these hardships that we're facing now," Brugge says. "We all need to work hard to make a difference for ...